Results 231 to 240 of about 755,388 (347)

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

Advanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei, Wuqiang Wen, Wenjun Zhang, Shujing Zhang, Ting Sun, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao, Aibin Liang, Baishan Jiang, Jing Yang   +32 more
wiley   +1 more source

Impact of TRMT6 on prognosis and immune microenvironment in ovarian cancer. [PDF]

Front Oncol
Zhao J, Wang X, Wang Y, Li N.
europepmc   +1 more source

Decoding Triphenotypic Neutrophils in Cervical Cancer Evolution and Targeting SPP1+/GBP1+/ELOVL5+ Tumor‐Associated Neutrophils to Sensitize Immunotherapy

Advanced Science, EarlyView.
The functional schematic diagram of tumor associated neutrophils. Abstract Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence
Xingyu Chang, Xinyu Qu, Tingting Ren, Tong Wu, Weiyong Gu, Jingxin Ding, Keqin Hua, Junjun Qiu   +7 more
wiley   +1 more source

Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives. [PDF]

Biomedicines
Dedes N, Liontos M, Haidopoulos D, Zagouri F, Angelou K, Svarna A, Michas A, Aravantinou Fatorou A, Andrikopoulou A, Dimopoulos MA.   +9 more
europepmc   +1 more source

Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges

, 2016
Mingo M. H. Yung, Hys Ngan, David W. Chan   +2 more
openalex   +2 more sources

Halorotetin B, A Novel Terpenoid Compound Derived from Marine Ascidian, Suppresses Tumor Growth by Targeting the Cell Cycle Regulator UBE2C

Advanced Science, EarlyView.
Halorotetin B, a novel small‐molecule terpenoid identified from an edible marine ascidian, exhibits strong anti‐tumor activity both in vitro and in vivo through direct targeting UBE2C to induce tumor cell cycle arrest and then lead tumor cell senescence. As a newly discovered UBE2C inhibitor, Halorotetin B can serve as a novel potential cell senescence
Shanhao Han, Jianhui Li, Yuting Zhu, Penghui Liu, Yaoyao Zheng, Muchun He, Bo Dong   +6 more
wiley   +1 more source

Proteomics discovery of MTDH and SND1 interaction vulnerabilities in ovarian cancer. [PDF]

Sci Rep
Esmaeili P, Nasimian A, Werner L, Junior SM, Jakobsson ME, Gerdtsson AS, Kazi JU, Levander F.   +7 more
europepmc   +1 more source

Targeting the Dynamics Between TAMs and CAR‐T Cells in Solid Tumor Therapies

Advanced Science, EarlyView.
This review highlights the critical role of tumor‐associated macrophages (TAMs) in affecting CAR‐T cell therapy effectiveness in solid tumors. TAMs contribute to immune suppression through cytokine secretion, immune checkpoint activation, and metabolic reprogramming, leading to CAR‐T cell exhaustion and reduced efficacy. The article explores strategies
Xiang Zhang, Hao Zheng, Zi‐Chang Liu, Ling‐Jie Luo, Xiao Dong, Xin‐Gang Cui, Yan‐Wei Wu, Liang Chen   +7 more
wiley   +1 more source

EMSY enhances glycolysis in ovarian cancer cells. [PDF]

Eur J Med Res
Wang S, Xie N, Zha P, Li Y, Wei M, Bai J, Zhao X.   +6 more
europepmc   +1 more source

AI‐Guided SERS Defines a Pan‐Cancer Diagnostic Biomarker

Advanced Science, EarlyView.
An AI‐enabled SERS platform integrates automated exosome enrichment with molecular fingerprinting to enable accurate early detection and differential diagnosis of ten common cancers. The system identifies exosomal dATP as a universal Raman biomarker, offering a scalable, noninvasive, and clinically translatable approach for precision oncology ...
Cai Zhang, Wen‐Hui Zhao, Duo Zuo, Tianxing Zhou, Wenjing Hou, Lingwei Wang, Shangheng Shi, Yang Yang, Yuanyuan Liu, Shao‐Kai Sun, Li Ren, Zhaoxiang Ye, Dingbin Liu, Dong Li, Xiaoyuan Chen, Jihui Hao   +15 more
wiley   +1 more source